The Utah life sciences sector is preparing to make a significant impact at the upcoming J.P. Morgan 43rd Annual Healthcare Conference, with BioUtah leading the state's representation. The conference, considered the largest investment symposium in the healthcare industry, will provide a critical platform for Utah to demonstrate its growing prominence in medical innovation and entrepreneurship.
Led by President and CEO Kelvyn Cullimore, BioUtah will represent over 2,000 life sciences companies across the state. The delegation aims to highlight Utah's unique strengths in medical device manufacturing, diagnostics, biotechnology, pharmaceuticals, and digital health.
Recent research from the University of Utah Kem C. Gardner Policy Institute underscores the state's remarkable performance in the life sciences sector. Utah consistently ranks among the top three states for life sciences growth, with the industry contributing $22.6 billion to the state's GDP and supporting approximately 180,000 jobs.
The conference presents a strategic opportunity for Utah's life sciences community to engage with industry leaders and investors. BioUtah will co-host a networking reception, providing a platform for stakeholders to connect and explore collaborative opportunities.
Following the conference, BioUtah will continue its momentum by hosting the Entrepreneur and Investor Life Sciences Summit, an event designed to further showcase the state's startup ecosystem. The summit, presented in partnership with the University of Utah's Technology Licensing Office, will bring together entrepreneurs, investors, academic researchers, and industry professionals.
Utah's life sciences sector represents a compelling narrative of innovation, collaboration, and economic potential. By participating in the J.P. Morgan Healthcare Conference, BioUtah aims to position the state as a critical hub for medical technology and biotechnology advancement.
